Literature DB >> 26797908

Biofilm Antimicrobial Susceptibility Increases With Antimicrobial Exposure Time.

Paulo Castaneda1,2, Alex McLaren3,4,5,6, Gamuchirai Tavaziva6, Derek Overstreet5,6.   

Abstract

BACKGROUND: The antimicrobial concentration required to kill all the bacteria in a biofilm, known as the minimum biofilm eradication concentration (MBEC), is typically determined in vitro by exposing the biofilm to serial concentrations of antimicrobials for 24 hours or less. Local delivery is expected to cause high local levels for longer than 24 hours. It is unknown if longer antimicrobial exposures require the same concentration to eradicate bacteria in biofilm. Questions/purposes Does MBEC change with increased antimicrobial exposure time?
METHODS: Biofilms were grown for 24 hours using five pathogens (methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa) and then exposed to four antimicrobials regimens: tobramycin, vancomycin, and tobramycin combined with vancomycin in 3:1 and 1:1 ratios by weight in concentrations of 62.5, 125, 250, 500, 1000, 2000, 4000, and 8000 μg/mL for three durations, 1, 3, and 5 days, in triplicate. MBEC was measured as the lowest concentration that killed all bacteria in the biofilm determined by 21-day subculture.
RESULTS: MBEC was lower when antimicrobial exposure time was longer. For the staphylococcus species, the MBEC was lower when exposure time was 5 days than 1 day in 11 of 12 antimicrobial/microorganism pairs. The MBEC range for these 11 pairs on Day 1 was 4000 to > 8000 μg/mL and on Day 5 was < 250 to 8000 μg/mL. MBEC for tobramycin/P. aeruginosa was 2000 μg/mL on Day 1 and ≤ 250 μg/mL on Day 5, and for E. coli, 125 μg/mL on Day 1 and ≤ 62.5 on Day 5.
CONCLUSIONS: Although antimicrobial susceptibility was lower for longer exposure times in the microorganisms we studied, confirmation is required for other pathogens. Clinical Relevance One-day MBEC assays may overestimate the local antimicrobial levels needed to kill organisms in biofilm if local levels are sustained at MBEC or above for longer than 24 hours. Future studies are needed to confirm that antimicrobial levels achieved clinically from local delivery are above the MBEC at relevant time points and to confirm that MBEC for in vitro microorganisms accurately represents MBEC of in vivo organisms in an clinical infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26797908      PMCID: PMC4887352          DOI: 10.1007/s11999-016-4700-z

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  19 in total

1.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

Review 2.  Biofilms and antimicrobial resistance.

Authors:  Robin Patel
Journal:  Clin Orthop Relat Res       Date:  2005-08       Impact factor: 4.176

Review 3.  Persister cells, dormancy and infectious disease.

Authors:  Kim Lewis
Journal:  Nat Rev Microbiol       Date:  2006-12-04       Impact factor: 60.633

4.  In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms.

Authors:  Sibel Dosler; Emel Mataraci
Journal:  Peptides       Date:  2013-08-26       Impact factor: 3.750

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

6.  Biofilm bacteria: formation and comparative susceptibility to antibiotics.

Authors:  Merle E Olson; Howard Ceri; Douglas W Morck; Andre G Buret; Ronald R Read
Journal:  Can J Vet Res       Date:  2002-04       Impact factor: 1.310

7.  Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.

Authors:  Issam Raad; Hend Hanna; Ying Jiang; Tanya Dvorak; Ruth Reitzel; Gassan Chaiban; Robert Sherertz; Ray Hachem
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

8.  Detachment characteristics and oxacillin resistance of Staphyloccocus aureus biofilm emboli in an in vitro catheter infection model.

Authors:  C A Fux; S Wilson; P Stoodley
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

9.  Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.

Authors:  Warren E Rose; Peter T Poppens
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

Review 10.  Small colony variants (SCVs) of Staphylococcus aureus--a bacterial survival strategy.

Authors:  Barbara C Kahl
Journal:  Infect Genet Evol       Date:  2013-05-27       Impact factor: 3.342

View more
  29 in total

1.  Surfactants: Role in biofilm management and cellular behaviour.

Authors:  Steven L Percival; Dieter Mayer; Robert S Kirsner; Greg Schultz; Dot Weir; Sashwati Roy; Afsaneh Alavi; Marco Romanelli
Journal:  Int Wound J       Date:  2019-03-18       Impact factor: 3.315

2.  CORR Insights®: Is Implant Coating With Tyrosol- and Antibiotic-loaded Hydrogel Effective in Reducing Cutibacterium (Propionibacterium) acnes Biofilm Formation? A Preliminary In Vitro Study.

Authors:  Paul Stoodley
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

3.  Temperature-responsive PNDJ hydrogels provide high and sustained antimicrobial concentrations in surgical sites.

Authors:  Derek J Overstreet; Vajra S Badha; John M Heffernan; Erin P Childers; Rex C Moore; Brent L Vernon; Alex C McLaren
Journal:  Drug Deliv Transl Res       Date:  2019-08       Impact factor: 4.617

4.  Effect on total microbial load and community composition with two vs six-week topical Cadexomer Iodine for treating chronic biofilm infections in diabetic foot ulcers.

Authors:  Matthew Malone; Saskia Schwarzer; Michael Radzieta; Thomas Jeffries; Annie Walsh; Hugh G Dickson; Grace Micali; Slade O Jensen
Journal:  Int Wound J       Date:  2019-09-05       Impact factor: 3.315

Review 5.  Targeting microbial biofilms: current and prospective therapeutic strategies.

Authors:  Hyun Koo; Raymond N Allan; Robert P Howlin; Paul Stoodley; Luanne Hall-Stoodley
Journal:  Nat Rev Microbiol       Date:  2017-09-25       Impact factor: 60.633

6.  Chlorhexidine Antiseptic Irrigation Eradicates Staphylococcus epidermidis From Biofilm: An In Vitro Study.

Authors:  Kenneth Schmidt; Chris Estes; Alex McLaren; Mark J Spangehl
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

7.  Large variations in clinical antibiotic activity against Staphylococcus aureus biofilms of periprosthetic joint infection isolates.

Authors:  Jonathan B Mandell; Sara Orr; John Koch; Blake Nourie; Dongzhu Ma; Daniel D Bonar; Neel Shah; Kenneth L Urish
Journal:  J Orthop Res       Date:  2019-04-08       Impact factor: 3.494

8.  Adjuvant antibiotic-loaded bone cement: Concerns with current use and research to make it work.

Authors:  Edward M Schwarz; Alex C McLaren; Thomas P Sculco; Barry Brause; Mathias Bostrom; Stephen L Kates; Javad Parvizi; Volker Alt; William V Arnold; Alberto Carli; Antonia F Chen; Hyonmin Choe; Débora C Coraça-Huber; Michael Cross; Michelle Ghert; Noreen Hickok; Jessica Amber Jennings; Manjari Joshi; Willem-Jan Metsemakers; Mark Ninomiya; Kohei Nishitani; Irvin Oh; Douglas Padgett; Benjamin Ricciardi; Kordo Saeed; Parham Sendi; Bryan Springer; Paul Stoodley; Joseph C Wenke
Journal:  J Orthop Res       Date:  2020-03-02       Impact factor: 3.102

9.  Targeting microbial biofilms: by Arctium lappa l. synthesised biocompatible CeO2-NPs encapsulated in nano-chitosan.

Authors:  Bushra Uzair; Nousheen Akhtar; Shamaila Sajjad; Asma Bano; Fehmida Fasim; Naheed Zafar; Sajjad Ahmed Khan Leghari
Journal:  IET Nanobiotechnol       Date:  2020-05       Impact factor: 1.847

10.  A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms.

Authors:  Christian Schütz; Duy-Khiet Ho; Mostafa Mohamed Hamed; Ahmed Saad Abdelsamie; Teresa Röhrig; Christian Herr; Andreas Martin Kany; Katharina Rox; Stefan Schmelz; Lorenz Siebenbürger; Marius Wirth; Carsten Börger; Samir Yahiaoui; Robert Bals; Andrea Scrima; Wulf Blankenfeldt; Justus Constantin Horstmann; Rebekka Christmann; Xabier Murgia; Marcus Koch; Aylin Berwanger; Brigitta Loretz; Anna Katharina Herta Hirsch; Rolf Wolfgang Hartmann; Claus-Michael Lehr; Martin Empting
Journal:  Adv Sci (Weinh)       Date:  2021-03-18       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.